Verana Health is a company.
Verana Health has raised $280.0M across 3 funding rounds.
Key people at Verana Health.
Verana Health has raised $280.0M in total across 3 funding rounds.
Key people at Verana Health.
# Verana Health: High-Level Overview
Verana Health is a healthcare data and analytics company that transforms real-world clinical data into actionable insights to accelerate medical innovation.[1][2] Founded in 2018 as a partnership between leading medical associations, physicians, and investors, the company has built one of the largest clinical databases in medicine by partnering with specialty medical societies and connecting data from over 20,000 healthcare providers across 70 electronic health record (EHR) systems.[1][3]
The company serves three primary audiences: life sciences companies seeking real-world evidence for drug development, healthcare providers improving clinical outcomes and quality reporting, and clinicians advancing medical research.[3] Verana Health solves a critical healthcare problem—the difficulty of extracting meaningful insights from fragmented clinical data—by using artificial intelligence and machine learning to unlock real-world evidence that traditionally takes years to generate through conventional clinical trials.[2][4] This acceleration allows patients to receive needed treatments and care significantly faster than the traditional evidence-collection model permits.[4]
# Core Differentiators
# Role in the Broader Healthcare Landscape
Verana Health operates at the intersection of two powerful healthcare trends: the shift toward real-world evidence (RWE) as a complement to traditional clinical trials, and the growing recognition that AI and machine learning can unlock value from existing clinical data.[4] The timing is critical—regulators, including the FDA, increasingly accept real-world data to inform drug approvals and safety monitoring, creating regulatory tailwinds for companies that can deliver high-quality evidence quickly.[4]
The company influences the broader ecosystem by demonstrating that specialty medical societies can become data assets rather than passive observers. By positioning clinicians and medical associations as partners rather than data sources, Verana Health has created a model that other healthcare data companies are beginning to emulate. This approach also accelerates the pace at which medical innovation reaches patients, particularly in specialty fields where traditional clinical trials are slow and expensive.[1][6]
# Quick Take & Future Outlook
Verana Health is well-positioned to capture significant value as healthcare systems, life sciences companies, and regulators increasingly prioritize real-world evidence in decision-making. The company's expansion beyond ophthalmology and urology into additional specialties, combined with deepening partnerships (such as its recent collaboration with Foundation Fighting Blindness on inherited retinal diseases), suggests a trajectory toward becoming the de facto real-world data infrastructure for specialty medicine.[6]
The key question ahead is whether Verana Health can maintain its clinical credibility and data quality while scaling to serve broader therapeutic areas and larger patient populations. As healthcare data becomes more valuable and competitive, the company's ability to preserve trust with medical societies and clinicians—its core differentiator—will determine whether it remains a category leader or becomes a commodity data provider. The convergence of regulatory acceptance for RWE, AI advancement, and clinician demand for evidence-driven practice creates a favorable environment for Verana Health's continued growth and influence.
Verana Health has raised $280.0M in total across 3 funding rounds.
Verana Health's investors include ARCH Venture Partners, Define Ventures, Foresite Capital, Gigascale Capital, GV, Jetstream, Khosla Ventures, Kleiner Perkins, Obvious Ventures, VZVC, Marc Benioff, William Miller.
Verana Health has raised $280.0M across 3 funding rounds. Most recently, it raised $150.0M Series E in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $150.0M Series E | ARCH Venture Partners, Define Ventures, Foresite Capital, Gigascale Capital, GV, Jetstream, Khosla Ventures, Kleiner Perkins, Obvious Ventures, VZVC, Marc Benioff, William Miller | |
| Feb 1, 2020 | $100.0M Series D | .406 Ventures, ARCH Venture Partners, Foresite Capital, GV, Sandbox Industries, VZVC | |
| Jul 1, 2018 | $30.0M Series C | ARCH Venture Partners, Define Ventures, Foresite Capital, Gigascale Capital, GV, Jetstream, Khosla Ventures, Kleiner Perkins, Obvious Ventures, VZVC, Marc Benioff, William Miller |
